葡萄糖皮质类药物通过HNF1在胰腺β细胞中减少Slc2a2 (GLUT2) 基因表达
Journal of molecular endocrinology
|December 17, 2024
概括
葡萄糖皮质类药物,像德克萨米他一样,通过抑制HNF1α/HNF1β转录因子,减少胰腺β细胞中的Slc2a2基因表达. 这揭示了葡萄糖皮质类药物诱导的糖尿病和β细胞功能障碍的机制.
科学领域:
- * 分子内分泌学 * 分子内分泌学
- * 糖尿病病理生理学
- * 基因调控 * 基因调控
背景情况:
- * 葡萄糖转运体2型 (GLUT2) 对于胰腺β细胞中的胰岛素分泌至关重要,其低表达与2型糖尿病有关.
- * 葡萄糖皮质体,通过葡萄糖皮质体受体 (GR),可以诱导β细胞功能障碍和糖尿病,但影响Slc2a2基因表达的潜在机制尚不清楚.
研究的目的:
- * 研究葡萄糖皮质类药物对胰腺β细胞中Slc2a2基因表达的影响.
- * 为了确定参与Slc2a2.2.通过葡萄糖皮质体介导抑制的调节元件和转录因子.
- *阐明了将葡萄糖皮质醇暴露与β细胞功能障碍联系起来的机制.
主要方法:
- *对MIN6β细胞系中GSIS相关基因表达的定量分析.
- *生物信息学分析和记者测试以确定Slc2a2基因增强剂.
- * 德克萨米他 (DEX) 和GR操纵,以评估对基因表达和转录因子活性的影响.
主要成果:
- * 甲 (DEX) 在MIN6β细胞中选择性地降低了Slc2a2mRNA的表达.
- * 一个增强元件 (E3c),位于Slc2a2的40kb下游,调解了DEX诱导的抑制.
- *DEX和GR抑制了HNF1α和HNF1β的转录活性,这是E3c增强剂的关键激活剂.
结论:
- * 葡萄糖皮质激素诱导的Slc2a2抑制通过E3c增强剂发生,并且涉及HNF1α/HNF1β活性下降.
- * 这项研究揭示了葡萄糖皮质醇诱导的β细胞功能障碍和糖尿病的新机制.
- *研究结果提供了HNF1α/HNF1β,GR和β细胞功能在糖尿病发病过程中的功能联系.
相关概念视频
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Cell Specific Gene Expression
13.4K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.4K
Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297


